[go: up one dir, main page]

WO2007031727A3 - Systeme - Google Patents

Systeme Download PDF

Info

Publication number
WO2007031727A3
WO2007031727A3 PCT/GB2006/003367 GB2006003367W WO2007031727A3 WO 2007031727 A3 WO2007031727 A3 WO 2007031727A3 GB 2006003367 W GB2006003367 W GB 2006003367W WO 2007031727 A3 WO2007031727 A3 WO 2007031727A3
Authority
WO
WIPO (PCT)
Prior art keywords
ncs
delivering
calcium sensor
neuronal calcium
neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/003367
Other languages
English (en)
Other versions
WO2007031727A2 (fr
Inventor
Liang-Fong Wong
Nicholas Mazarakis
Susan Kingsman
Ping Yip
Jonathan Corcoran
Stephen Mcmahon
Malcom Maden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Oxford Biomedica UK Ltd
Original Assignee
Kings College London
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London, Oxford Biomedica UK Ltd filed Critical Kings College London
Priority to EP06779383A priority Critical patent/EP1937820A2/fr
Publication of WO2007031727A2 publication Critical patent/WO2007031727A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007031727A3 publication Critical patent/WO2007031727A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un système capable d'amener sur une cellule cible un détecteur 1 de calcium neuronal (NCS-1), ou une séquence nucléotide codant NCS-1, de façon à favoriser l'excroissance des neurites. Ce système convient à la fabrication d'une composition pharmaceutique destinée au traitement d'un état tel que les lésions de la moelle épinière.
PCT/GB2006/003367 2005-09-13 2006-09-11 Systeme Ceased WO2007031727A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06779383A EP1937820A2 (fr) 2005-09-13 2006-09-11 Systeme pour delivrer de neuronal calcium sensor-1 (ncs-1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0518674.7 2005-09-13
GB0518674A GB0518674D0 (en) 2005-09-13 2005-09-13 System

Publications (2)

Publication Number Publication Date
WO2007031727A2 WO2007031727A2 (fr) 2007-03-22
WO2007031727A3 true WO2007031727A3 (fr) 2008-05-15

Family

ID=35221413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003367 Ceased WO2007031727A2 (fr) 2005-09-13 2006-09-11 Systeme

Country Status (3)

Country Link
EP (1) EP1937820A2 (fr)
GB (1) GB0518674D0 (fr)
WO (1) WO2007031727A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3432911B1 (fr) * 2016-03-23 2025-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Agonistes du capteur de calcium neuronal 1 pour traiter le syndrome de wolfram
CN112852976B (zh) * 2021-03-17 2023-10-31 湖北省农业科学院畜牧兽医研究所 蛋鸡ncs1基因中与后期产蛋性状相关的分子标记及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075135A1 (fr) * 2000-03-30 2001-10-11 Oxford Biomedica (Uk) Limited Recepteur de l'acide retinoique $g(b)2, ses antagonistes et vecteurs de therapie genique pour le traitement de troubles neurologiques
EP1250931A1 (fr) * 2001-04-17 2002-10-23 F. Hoffmann-La Roche Ag Nouvelle utilisation du neuronal calcium sensor-1 (ncs-1) pour le traitement de troubles du système nerveux central et pour le développement d'agents thérapeutiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075135A1 (fr) * 2000-03-30 2001-10-11 Oxford Biomedica (Uk) Limited Recepteur de l'acide retinoique $g(b)2, ses antagonistes et vecteurs de therapie genique pour le traitement de troubles neurologiques
EP1250931A1 (fr) * 2001-04-17 2002-10-23 F. Hoffmann-La Roche Ag Nouvelle utilisation du neuronal calcium sensor-1 (ncs-1) pour le traitement de troubles du système nerveux central et pour le développement d'agents thérapeutiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAWASAKI T, ET AL.: "SPATIOTEMPORAL DISTRIBUTION OF NEURONAL CALCIUM SENSOR-1 IN THE DEVELOPING RAT SPINAL CORD", THE JOURNAL OF COMPARATIVE NEUROLOGY, vol. 460, 2003, pages 465 - 475, XP009076437 *
NAKAMURA T Y, ET AL.: "NOVEL ROLE OF NEURONAL CA2+ SENSOR-1 AS A SURVIVAL FACTOR UP-REGULATED IN INJURED NEURONS", THE JOURNAL OF CELL BIOLOGY, vol. 172, no. 7, 27 March 2006 (2006-03-27), pages 1081 - 1091, XP002412312 *
PAN C-Y, ET AL.: "ALTERATIONS IN EXOCYTOSIS INDUCED BY NEURONAL CA2+ SENSOR-1 IN BOVINE CHROMAFFIN CELLS", THE JOURNAL OF NEUROSCIENCE, vol. 22, no. 7, 2002, pages 2427 - 2433, XP002412311 *

Also Published As

Publication number Publication date
EP1937820A2 (fr) 2008-07-02
GB0518674D0 (en) 2005-10-19
WO2007031727A2 (fr) 2007-03-22

Similar Documents

Publication Publication Date Title
WO2007006307A3 (fr) Nouveaux sels de monoalkylesters d'acide fumarique et leur utilisation pharmaceutique
TW200612892A (en) Novel compounds
WO2006135915A3 (fr) Methodes et compositions de traitement de maladies osseuses degeneratives
WO2007016538A3 (fr) Preparation et utilisation de derives aminoacides biphenyle pour traiter l'obesite
WO2006128693A3 (fr) Derives de 2-oxo-1-pyrrolidine, procedes de preparation de ceux-ci et utilisations de ceux-ci
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2008014311A3 (fr) Inhibiteurs de l'undécaprényl pyrophosphate synthase
WO2007120689A3 (fr) Procédés d'utilisation du récepteur gpr119 pour identifier des composés utiles pour augmenter la masse osseuse chez un individu
WO2008057933A3 (fr) Procédés de traitement de la douleur neuropathique par la modulation des voies de la glycogénolyse ou de la glycolyse
WO2008065372A3 (fr) Polypeptides d'érythropoïétine modifiés et utilisation de ceux-ci dans des traitements
WO2008014307A3 (fr) Inhibiteurs de l'undécaprényl pyrophosphate synthase
WO2007025709A3 (fr) Composes organiques
WO2008148873A3 (fr) Compositions d'hydroxyproline et leurs utilisations
WO2007068894A3 (fr) Nouveaux composes
WO2010130830A3 (fr) Séquences d'acides aminés dirigées contre la sclérostine et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies des os
WO2008141308A3 (fr) Expression génique et douleur
WO2008064202A3 (fr) Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium
TW200745003A (en) Novel compounds
TW200621690A (en) Novel compounds
WO2009062576A8 (fr) Nouveaux dérivés de benzimidazole-dihydrothiadiazinone en tant que des inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques les comprenant
WO2008109165A3 (fr) Membranes de régénération osseuse guidée minéralisées et procédés pour les fabriquer
WO2010019511A3 (fr) Rifamycines phosphonées et leurs utilisations pour la prévention et le traitement d'infections des os et des articulations
WO2008069876A3 (fr) Peptides amides stimulant les neurones dopaminergiques pour la régulation dopaminergique à la hausse du système nerveux central
WO2009047513A3 (fr) Composé, utilisation et procédé
WO2009115252A3 (fr) Pyrazolamides substitués et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006779383

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006779383

Country of ref document: EP